Maastricht University is host to the psychopharmacology department (Psychopharmacology in Maastricht) where various researchers are investigating the effects of psychedelics.
Maastricht University
Much of the early research at Maastricht University was focused on (the dangers of) MDMA. Other research is ongoing into cannabis, microdosing, and novel psychoactive substances (NPS).
The university is cooperating on research with Silo Pharma.
Part of the work done at Maastricht University is sponsored by the Beckley Foundation (article).
Key Staff
- Johannes Ramaekers
- Kim Kuypers
- Rob Markus
- Eef Theunissen
- Natasha Mason
- Nadia Hutten
You can find all staff on their website.
News
- MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers (Psilocybin Alpha, January 2021)
- Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease (Psilocybin Alpha, December 2020)
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Related Course(s)
Psychedelic Medicine: The Therapeutic Potential of Mind-Altering SubstancesPsychedelic Medicine: The Therapeutic Potential of Mind-Altering Substances is a course offered by the University of Maastricht.